EGTX — Egetis Therapeutics AB (publ) Cashflow Statement
0.000.00%
Last trade - 00:00- SEK2.22bn
- SEK2.08bn
- SEK62.40m
Annual cashflow statement for Egetis Therapeutics AB (publ), fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -105 | -194 | -327 | -343 | -342 |
| Depreciation | |||||
| Non-Cash Items | 0.228 | 9.4 | 17.7 | 27 | 49.1 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -28.3 | 10.9 | 30.7 | 88.3 | 26 |
| Change in Accounts Receivable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -130 | -174 | -278 | -228 | -267 |
| Capital Expenditures | -0.172 | 0 | 0 | — | -1.5 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -5.79 | -1.7 | 0 | -1.2 | -1.3 |
| Acquisition of Business | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -5.96 | -1.7 | 0 | -1.2 | -2.8 |
| Financing Cash Flow Items | — | — | 0.1 | -0.1 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -8.9 | 156 | 459 | 271 | 140 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -144 | -16.3 | 176 | 47.6 | -135 |